Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4UMR

Structure of MELK in complex with inhibitors

Summary for 4UMR
Entry DOI10.2210/pdb4umr/pdb
Related4D2T 4D2V 4D2W 4UMP 4UMQ 4UMT 4UMU
DescriptorMATERNAL EMBRYONIC LEUCINE ZIPPER KINASE, 4-fluoro-N-(1,2,3,4-tetrahydroisoquinolin-7-yl)benzamide (3 entities in total)
Functional Keywordstransferase, fragment based drug design
Biological sourceHOMO SAPIENS (HUMAN)
Cellular locationCell membrane ; Peripheral membrane protein : Q14680
Total number of polymer chains1
Total formula weight41162.58
Authors
Primary citationJohnson, C.N.,Berdini, V.,Beke, L.,Bonnet, P.,Brehmer, D.,Coyle, J.E.,Day, P.J.,Frederickson, M.,Freyne, E.J.E.,Gilissen, R.A.H.J.,Hamlett, C.C.F.,Howard, S.,Meerpoel, L.,Mcmenamin, R.,Patel, S.,Rees, D.C.,Sharff, A.,Sommen, F.,Wu, T.,Linders, J.T.M.
Fragment-Based Discovery of Type I Inhibitors of Maternal Embryonic Leucine Zipper Kinase
Acs Med.Chem.Lett., 6:25-, 2015
Cited by
PubMed Abstract: Fragment-based drug design was successfully applied to maternal embryonic leucine zipper kinase (MELK). A low affinity (160 μM) fragment hit was identified, which bound to the hinge region with an atypical binding mode, and this was optimized using structure-based design into a low-nanomolar and cell-penetrant inhibitor, with a good selectivity profile, suitable for use as a chemical probe for elucidation of MELK biology.
PubMed: 25589925
DOI: 10.1021/ML5001245
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon